Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres.
Metachromatic leukodystrophy (MLD) is an autosomal recessive disease caused by mutations in the gene encoding the lysosomal enzyme arylsulfatase A (ASA). In MLD, accumulation of the substrate, sulfated glycoprotein, in the central and peripheral nervous systems results in progressive motor and mental deterioration. Neural progenitor cells are thought to be useful for cell replacement therapy and for cell-mediated gene therapy in neurodegenerative diseases. In the present study, we examined the feasibility of ex vivo gene therapy for MLD using neural progenitor cells. Neural progenitor cells (neurospheres) were prepared from the striatum of E14 embryo MLD knockout mice or GFP transgenic mice and were transduced with the VSV pseudotyped HIV vector carrying the ASA gene (HIV-ASA). For in vivo study, neurospheres from GFP mice were transduced with HIV-ASA and inoculated into the brain parenchyma of adult MLD mice. HIV vector-transduced progenitor cells retained the potential for differentiation into neurons, astrocytes and oligodendrocytes in vitro. Expression of ASA in neurospheres transduced with HIV-ASA was confirmed by spectrophotometric enzyme assay and Western blotting. In vivo, GFP-positive cells were detectable 1 month after injection. These cells included GFAP- and MAP2-positive cells. Immunohistochemistry using anti-ASA antibody demonstrated localization of ASA in both GFP-positive and -negative cells. Partial clearance of accumulated sulfatide was confirmed in vivo in MLD knockout mice. The present findings suggest that ASA enzyme is released from migrated neurospheres and is able to digest sulfatide in surrounding cells. Our results suggest the potential of genetically engineered neural progenitor cells (neurospheres) for ex vivo therapy in MLD.
Kawabata
Ken
K
Department of Biochemistry and Molecular Biology, Nippon Medical School, Japan.
Migita
Makoto
M
Mochizuki
Hideki
H
Miyake
Koichi
K
Igarashi
Tsutomu
T
Fukunaga
Yoshitaka
Y
Shimada
Takashi
T
D000818:Animals; D001921:Brain / Q000201:enzymology / Q000503:physiopathology / Q000601:surgery; D002460:Cell Line; D002478:Cells, Cultured; D002553:Cerebroside-Sulfatase / Q000172:deficiency / Q000235:genetics*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006085:Graft Survival / Q000502:physiology; D049452:Green Fluorescent Proteins; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D007966:Leukodystrophy, Metachromatic / Q000628:therapy*; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D018874:Spheroids, Cellular / Q000166:cytology / Q000201:enzymology / Q000637:transplantation*; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000166:cytology / Q000201:enzymology; D013433:Sulfoglycosphingolipids / Q000378:metabolism; D014162:Transfection / Q000379:methods*; D016896:Treatment Outcome
D005904:Glial Fibrillary Acidic Protein; D008869:Microtubule-Associated Proteins; C079240:Mtap2 protein, mouse; D013433:Sulfoglycosphingolipids; D049452:Green Fluorescent Proteins; D002553:Cerebroside-Sulfatase